USC Focuses on Prevention as They Develop Alzheimer's Vaccine

The study suggests that by using the anti-amyloid-beta vaccine during the early stages of Alzheimer’s disease it can increase its effectiveness. Moreover, people at risk for the said disease can also be vaccinated using the same. Nonetheless, if the vaccine proceeds with success during the preclinical trials conducted by researchers, they can begin testing it on people with a high risk for the disease and those in the early stages as well within the next three to five years.

Scientists are about to begin testing the vaccine on humans once they receive the appropriate regulatory approval. They believe that the research can be of great benefit to millions of people who are likely to suffer and are suffering from the early stages of the disease.